111
Participants
Start Date
July 24, 2019
Primary Completion Date
March 31, 2021
Study Completion Date
March 31, 2021
TQ-B3101
TQ-B3101 300 mg given orally in fasting conditions, twice daily in 28-day cycle.
RECRUITING
Beijing Cancer Hospital, Beijing
NOT_YET_RECRUITING
Chinese PLA General Hospital, Beijing
NOT_YET_RECRUITING
Tumor hospital, Chinese academy of medical sciences, Beijing
RECRUITING
The second affiliated hospital of dalian medical university, Dalian
NOT_YET_RECRUITING
Second hospital of jilin university, Changchun
RECRUITING
Affiliated tumor hospital of Harbin medical university, Harbin
RECRUITING
Shanghai Jiaotong University Affiliated Chest Hospital, Shanghai
RECRUITING
Anhui chest hospital, Hefei
NOT_YET_RECRUITING
Qilu Hospital of Shandong University, Jinan
NOT_YET_RECRUITING
Qingdao University Medical College Hospital, Qingdao
NOT_YET_RECRUITING
Linyi tumor hospital, Linyi
NOT_YET_RECRUITING
Tianjin tumor hospital, Tianjin
RECRUITING
Sir Run Run Shaw Hospital School of Medical,Zhejiang University, Hangzhou
NOT_YET_RECRUITING
Fujian Tumor Hospital, Fuzhou
RECRUITING
Hunan provincial tumor hospital, Changsha
RECRUITING
Xiangya Hospital of Centre-south University, Changsha
NOT_YET_RECRUITING
Henan Provincial People's Hospital, Zhengzhou
NOT_YET_RECRUITING
Henan Tumor Hospital, Zhengzhou
RECRUITING
Affiliated tumor hospital of sun yat-sen university, Guangzhou
RECRUITING
The first affiliated hospital of guangdong pharmaceutical university, Guangzhou
RECRUITING
The first affiliated hospital of guangzhou medical college, Guangzhou
RECRUITING
The first affiliated hospital of xi 'an jiaotong university, Xi’an
Lead Sponsor
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
INDUSTRY